News
March 26, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial ...
Hosted on MSN1mon
Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to TradeShares of OptiNose (OPTN) have gained 58.6% over the past four weeks to close the last trading session at $9.15, but there could still be a solid upside left in the stock if short-term price ...
OptiNose (OPTN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.35 per share a year ago. These figures are ...
OPTINOSE ($OPTN) posted quarterly earnings results on Wednesday, March 26th. The company reported earnings of -$0.03 per share, beating estimates of -$0.72 by $0.69 ...
Hosted on MSN1mon
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by ParatekShares of OptiNose OPTN soared 52.5% on Thursday after the company announced that it is set to be acquired by Paratek Pharmaceuticals, a private biotech. This deal will add OPTN’s approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback